Literature DB >> 10799353

Treatment of menstrual migraine with prostaglandin synthesis inhibitor mefenamic acid: double-blind study with placebo.

N S Al-Waili1.   

Abstract

The therapeutic effect of mefenamic acid, prostaglandin synthesis inhibitor, on pain of acute menstrual migraine and at the following days during menstrual bleeding period was studied and compared with placebo. 24 patients, 18 to 35 years old, with menstrual migraine were entered for study. They had regular menstrual cycles and they had been diagnosed as experiencing menstrual migraine without aura for more than one year. The patients were treated for 2 consecutive menstrual cycles, one cycle with 500 mg mefenamic acid and one cycle with placebo. Each drug was given at beginning of complaint and similar dose was repeated 8 hourly at following days during the menstrual bleeding period (Total dosage used 1500 mg per day). The use of medication was double blind. Pain intensity was rated by means of a 4 points scale and functional disability was rated from 0 to 3. Results showed that 79.16% of the patients showed significant pain relief with mefenamic acid as compared to 16.6% with placebo. The mean pain score of the mefenamic acid treated attacks decreased significantly from 2.46 +/- 0.5 to 0.62 +/- 1.0 at 2hr postdose. 83.3% of patients treated with mefenamic acid was able to function with or without little effort whereas 12.4% restored their activities with placebo. All the patients (100%) who showed significant initial responses to placebo experienced headache recurrence as compared to 26.3% with mefenamic acid. When considering mean pain scores, percentage of patients with pain free at 2h postdose, percentage of patients required rescue treatment, percentage of patients with headache recurrence and percentages of patients restored full activities, mefenamic acid is significantly superior to placebo in treatment of acute menstrual migraine. It might be concluded that mefenamic acid is safe and effective for treatment of acute menstrual migraine.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10799353

Source DB:  PubMed          Journal:  Eur J Med Res        ISSN: 0949-2321            Impact factor:   2.175


  10 in total

1.  Menstrual migraine: update on pathophysiology and approach to therapy and management.

Authors:  Anne H Calhoun
Journal:  Curr Treat Options Neurol       Date:  2012-02       Impact factor: 3.598

Review 2.  Menstrual migraine: diagnosis and treatment.

Authors:  C L Lay; A M Mascellino
Journal:  Curr Pain Headache Rep       Date:  2001-04

Review 3.  Prevention and treatment of menstrual migraine.

Authors:  E Anne MacGregor
Journal:  Drugs       Date:  2010-10-01       Impact factor: 9.546

4.  Hormonal contraceptive options for women with headache: a review of the evidence.

Authors:  Andrea G Edlow; Deborah Bartz
Journal:  Rev Obstet Gynecol       Date:  2010

Review 5.  Adolescent issues in migraine: a focus on menstrual migraine.

Authors:  Christine L Lay; Susan W Broner
Journal:  Curr Pain Headache Rep       Date:  2008-10

Review 6.  Perimenstrual headache: treatment options.

Authors:  Katherine A Henry; Carl I Cohen
Journal:  Curr Pain Headache Rep       Date:  2009-02

Review 7.  Acute and Preventive Management of Migraine during Menstruation and Menopause.

Authors:  Raffaele Ornello; Eleonora De Matteis; Chiara Di Felice; Valeria Caponnetto; Francesca Pistoia; Simona Sacco
Journal:  J Clin Med       Date:  2021-05-24       Impact factor: 4.241

Review 8.  Preventative treatment of menstrual migraine.

Authors:  Christine L Lay; Susan W Broner
Journal:  Curr Pain Headache Rep       Date:  2007-06

Review 9.  Headache in Children and Adolescents.

Authors:  Christina Szperka
Journal:  Continuum (Minneap Minn)       Date:  2021-06-01

10.  Functional comparison of anoctamin 1 antagonists on human uterine smooth muscle contractility and excitability.

Authors:  Shunsuke Hyuga; Jennifer Danielsson; Joy Vink; Xiao Wen Fu; Ronald Wapner; George Gallos
Journal:  J Smooth Muscle Res       Date:  2018
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.